Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?
作者： Emmanuelle Norguet , Laetitia Dahan , Jean Gaudart , Mohamed Gasmi , L’houcine Ouafik
DOI: 10.1016/J.DLD.2011.06.002
关键词: Bevacizumab 、 Colorectal cancer 、 Irinotecan 、 Internal medicine 、 Regimen 、 Cetuximab 、 Chemotherapy 、 Oncology 、 Proportional hazards model 、 Performance status 、 Medicine 、 Hepatology 、 Gastroenterology
摘要: Abstract Background Chemotherapy combinations and addition of cetuximab or bevacizumab to chemotherapy have been shown improve overall survival metastatic colorectal cancer (CRC) patients. However, the efficacy when administered after failure is still unknown. Methods Fifty-eight consecutive patients diagnosed with advanced between treated following irinotecan were included in our analysis. A multivariate Cox model analysis was performed estimate effect previous regimen on survival. Results Thirteen (22.4%) pre-treated anti-VEGF agents. None them responded cetuximab, this subgroup presented a significantly decreased disease-specific as compared treatment-naive (9.1 months vs. 4.9 months; p = 0.026). This difference remained statistically significant adjusting for age, sex, performance status (PS), K-RAS (RR = 2.2; 95% CI: 1.1–4.5, = 0.03). Conclusion These study results suggest that therapy decrease efficiency.
archives-ouvertes.fr
elsevier.com
dldjournalonline.com 参考文章(12)
Lee M. Ellis, Epidermal growth factor receptor in tumor angiogenesis Hematology-oncology Clinics of North America. ,vol. 18, pp. 1007- 1021 ,(2004) , 10.1016/J.HOC.2004.06.002
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
Bruno Vincenzi, Daniele Santini, Antonio Russo, Michele Gavasci, Fabrizio Battistoni, Giordano Dicuonzo, Laura Rocci, Valerio Maria Rosaria, Nicola Gebbia, Giuseppe Tonini, Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan Pharmacogenomics. ,vol. 8, pp. 319- 327 ,(2007) , 10.2217/14622416.8.4.319
Yongping Crawford, Ian Kasman, Lanlan Yu, Cuiling Zhong, Xiumin Wu, Zora Modrusan, Josh Kaminker, Napoleone Ferrara, None, PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. ,vol. 15, pp. 21- 34 ,(2009) , 10.1016/J.CCR.2008.12.004
Derek J. Jonker, Chris J. O'Callaghan, Christos S. Karapetis, John R. Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott R. Berry, Marianne Krahn, Timothy Price, R. John Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, Malcolm J. Moore, Cetuximab for the Treatment of Colorectal Cancer The New England Journal of Medicine. ,vol. 357, pp. 2040- 2048 ,(2007) , 10.1056/NEJMOA071834
Jolien Tol, Miriam Koopman, Annemieke Cats, Cees J. Rodenburg, Geert J.M. Creemers, Jolanda G. Schrama, Frans L.G. Erdkamp, Allert H. Vos, Cees J. van Groeningen, Harm A.M. Sinnige, Dirk J. Richel, Emile E. Voest, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Ninja F. Antonini, Linda Mol, Johan H.J.M. van Krieken, Otilia Dalesio, Cornelis J.A. Punt, Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 360, pp. 563- 572 ,(2009) , 10.1056/NEJMOA0808268
Alicia Viloria-Petit, Janusz Rak, Serge Jothy, Daniel Hicklin, Robert S. Kerbel, Peter Bohlen, Jean Marc Schlaeppi, Tania Crombet, Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo A Role for Altered Tumor Angiogenesis Cancer Research. ,vol. 61, pp. 5090- 5101 ,(2001)
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Fortunato Ciardiello, Roberto Bianco, Roberta Caputo, Rosa Caputo, Vincenzo Damiano, Teresa Troiani, Davide Melisi, Ferdinando De Vita, Sabino De Placido, A. Raffaele Bianco, Giampaolo Tortora, Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy Clinical Cancer Research. ,vol. 10, pp. 784- 793 ,(2004) , 10.1158/1078-0432.CCR-1100-03
Alberto F. Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas, Cathy Eng, Ernst U. Steinhauer, Jana Prausova, Heinz-Josef Lenz, Christophe Borg, Gary Middleton, Hendrik Kröning, Gabriele Luppi, Oliver Kisker, Angela Zubel, Christiane Langer, Justin Kopit, Howard A. Burris, EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 2311- 2319 ,(2008) , 10.1200/JCO.2007.13.1193